GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (STU:XMS) » Definitions » EV-to-EBIT

Xtant Medical Holdings (STU:XMS) EV-to-EBIT : 2,969.74 (As of May. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Xtant Medical Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xtant Medical Holdings's Enterprise Value is €112.85 Mil. Xtant Medical Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €0.04 Mil. Therefore, Xtant Medical Holdings's EV-to-EBIT for today is 2,969.74.

The historical rank and industry rank for Xtant Medical Holdings's EV-to-EBIT or its related term are showing as below:

STU:XMS' s EV-to-EBIT Range Over the Past 10 Years
Min: -1408.59   Med: -8.48   Max: 308.08
Current: -1162.07

During the past 13 years, the highest EV-to-EBIT of Xtant Medical Holdings was 308.08. The lowest was -1408.59. And the median was -8.48.

STU:XMS's EV-to-EBIT is ranked worse than
100% of 458 companies
in the Medical Devices & Instruments industry
Industry Median: 20.17 vs STU:XMS: -1162.07

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Xtant Medical Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was €150.54 Mil. Xtant Medical Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €0.04 Mil. Xtant Medical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 0.03%.


Xtant Medical Holdings EV-to-EBIT Historical Data

The historical data trend for Xtant Medical Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings EV-to-EBIT Chart

Xtant Medical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.14 -145.12 -12.29 -10.21 86.77

Xtant Medical Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.45 -18.64 50.41 86.77 -1,681.57

Competitive Comparison of Xtant Medical Holdings's EV-to-EBIT

For the Medical Devices subindustry, Xtant Medical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xtant Medical Holdings's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's EV-to-EBIT falls into.



Xtant Medical Holdings EV-to-EBIT Calculation

Xtant Medical Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=112.850/0.038000000000001
=2,969.74

Xtant Medical Holdings's current Enterprise Value is €112.85 Mil.
Xtant Medical Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xtant Medical Holdings  (STU:XMS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Xtant Medical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=0.038000000000001/150.537745
=0.03 %

Xtant Medical Holdings's Enterprise Value for the quarter that ended in Mar. 2024 was €150.54 Mil.
Xtant Medical Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xtant Medical Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Xtant Medical Holdings (STU:XMS) Business Description

Traded in Other Exchanges
Address
664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Xtant Medical Holdings (STU:XMS) Headlines

No Headlines